Abstract: Systems, devices and methods for electric stimulation are provided.

Abstract: The present disclosure generally relates to topical compositions comprising a combination of at least one alpha-hydroxy acid (e.g., glycolic acid) combined with at least one beta-hydroxy acid (e.g., salicylic acid) in the presence of water-soluble polystyrenes or appropriate salts thereof. The present disclosure further provides methods of making and using such compositions.

Abstract: Described herein are compositions and methods for the treatment of contact lens discomfort (CLD) and/or lid wiper epitheliopathy (LWE). Such compositions comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of such compositions to the inner surface of the eyelid provides therapeutic benefit to patients suffering from contact lens discomfort (CLD) and/or lid wiper epitheliopathy (LWE).

Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

Abstract: The use of long-chain citric acid esters as additives in aqueous polymer dispersions for production of porous polymer coatings, preferably for production of porous polyurethane coatings, is described.

Abstract: A universal mineral based sunscreen that is good for all skin colors and prevents any ashy visual appearance on all colors of skin.

Abstract: A monolithic metal-organic framework (MOF) composite body is disclosed, comprising: MOF crystallites adhered to each other via a binder comprising MOF; and at least 0.15 vol % nanoparticles encapsulated in the MOF body. The nanoparticles have an average particle size corresponding to an average particle diameter in the range 3-200 nm. The nanoparticles may have photocatalytic activity. The MOF composite body is of use for treating water containing an organic dye, the photocatalytic reaction supported by the photocatalytic nanoparticles being a degradation reaction of the organic dye.

Abstract: Embodiments of the present invention generally concern pharmaceutical formulations and compositions and methods for using the pharmaceutical formulations and compositions which comprise derivatives of benzimidazole compounds, their racemic mixtures, their enantiomers, their complexes, their salts, and combinations thereof which have been found to be novel agonists of imidizoline receptors with surprising life extending efficacies due to their geroprotective (anti-geriatric) actions on pathologies associated with the aging processes in humans and animals.

Abstract: The invention relates to a lubricating member for a razor cartridge having a lubricating member comprising a carboxymethyl cellulose.

Abstract: The subject technology relates generally to pulmonary delivery of NSAIDs, such as aspirin.

Abstract: Testing peptides in in vitro models of neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease, Frontotemporal dementia, Amyotrophic lateral sclerosis, to evaluate systems and methods of treatment therefore.

Abstract: A cannabinoid formulation includes a cannabinoid composition, an anti-inflammatory ingredient, an additive, and a delivery vehicle. The cannabinoid composition is in the amount of 0.1% to 15% of the final concentration of the formulation. The anti-inflammatory ingredient is in the amount of 10% to 30% of the final concentration of the formulation. The additive is in the amount of 1% to 5% of the final concentration of the formulation. The cannabinoid formulation is designed to be administrated topically to a target area on a human.

Abstract: The present invention relates to an antimicrobial composition and more particularly to an antimicrobial composition at the pH of skin. The present invention provides an antimicrobial composition comprising: a. 0.5 to 20% by weight of a solvent comprising an alkyl glycol ether, b. 0.1 to 20% by weight of a carboxylic acid selected from an aromatic carboxylic acid having pKa greater than 4 or an aliphatic carboxylic acid having pKa greater than 4.5 or mixtures thereof c. 1 to 80% by weight of an anionic surfactant.

Abstract: Disclosed herein are novel drug carriers including a non-aqueous pH dependent release system and a non-aqueous pH dependent reassembly/assembly and reabsorption/absorption system. The carriers are capable of pH dependent release of biologically active agents and assembly or reassembly when the carrier transitions from a low pH environment, to a high pH environment and back to a low pH environment.

Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

Abstract: The present invention relates to an oral pharmaceutical composition containing pemetrexed as a water-soluble anticancer drug and a method of manufacturing the same, and more particularly to an oral pharmaceutical composition, in which an ion-binding complex of pemetrexed and a bile acid derivative as an oral absorption enhancer is formed, mixed with a pharmaceutical additive, and then provided in the form of a capsule or a tablet through pressing or included in the internal water phase of a w/o/w (water-in-oil-in-water) multiple nanoemulsion, thus increasing the oral bioavailability of pemetrexed as the water-soluble anticancer drug, whereby pemetrexed, which is currently administered only in the form of an injection formulation, can be manufactured into a formulation capable of being orally administered, ultimately alleviating inconvenience and problems with use of injection formulations, improving patient compliance and contributing to a reduction in medical expenses.

Abstract: The present disclosure relates to pharmaceutical compositions of tranexamic acid and methods of using the compositions. The pharmaceutical compositions of the present disclosure are stable and suitable for topical application.

Abstract: There is described herein the use of mirtazapine in methods for the treatment of inflammatory disorders, autoimmune disease, and PBC.

Abstract: A pharmaceutical composition for treating skin infections is described herein. A method using a pharmaceutical composition for treating skin infections is described herein. A pharmaceutical composition for treating skin infections may comprise, in 100 parts of the composition, 1-99 parts of a pharmaceutically acceptable excipient; 99-1 parts of a keratolytic; 99-1 parts ethyl pyruvate; and 99-1 parts povidone iodine. A method for treating skin infections may comprise topical application of a composition to an infected skin cell for a treatment period.

Abstract: Embodiments of the disclosure relate to the use of an IL-17 pathway inhibitor for treating chronic infections caused by one or more HPVs.

Abstract: A biphasic leave-on skin peel composition, being light-weight, with a pleasing feel upon application, with little to no skin irritation and discomfort. The composition includes at least one of each of alpha and beta hydroxy acids and high content of non-water miscible oil and is present from at least 20% by weight based on the total weight of the composition. The oily and water phases may be present in equal amounts (about 1:1). The composition includes water and alcohol as solvents in the water phase and may include phenylethyl resorcinol and other optional additives, may be devoid or essentially free of surfactant.

Abstract: Compositions for treating a sleep disorder or modifying or improving the sleep-wake cycle in a subject are disclosed herein. In some examples, the composition can comprise one or more sleep promoting active agents, one or more sleep quality active agents, one or more sleep recovery active agents, and optionally one or more next day active agents. The composition can provide an immediate burst release of the one or more sleep promoting active agents, a delayed burst or delayed sustained release of the one or more sleep quality active agents, a delayed burst or delayed sustained release of the one or more sleep recovery active agents, and a delayed burst or delayed sustained release of the one or more next day active agents. The composition can be provided as a daily oral uni-dosage form. Methods of making and using the compositions are also provided.

Abstract: A analgesic composition for topical application is provided that includes magnesium sulfate and a source of vitamin B12 in an amount effective for providing pain relief associated with peripheral neuropathy. The composition has a viscosity effective for allowing topical application of the composition to an afflicted area where the magnesium sulfate and vitamin B12 is absorbed through the dermis to the subcutaneous to provide pain relief relating to symptoms of peripheral neuropathy. The composition provides the novel benefits of being portable, easily dispensed, and provides a higher concentration of applied magnesium sulfate and vitamin B12 than the traditional dispensing method of Epsom Salt soaking solutions.

Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

Abstract: This patent pertains to selective inhibition of assembly of the membrane attack complex of complement by use of less than 1 kDa molecular weight forms of the aurin tricarboxylic acid synthetic complex (ATAC), and their derivatives. It further pertains to the use of these materials to treat human conditions where there is evidence of self destruction of host tissue by the membrane attack complex. These diseases include, but are not limited to, Alzheimer disease, age related macular degeneration, and atherosclerosis.

Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

Abstract: Methods of treating patients suffering from non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), including those also suffering from type II diabetes mellitus (T2DM), with a delayed release pharmaceutical composition comprising 6-mercaptopurine are disclosed.

Abstract: The magnetorheological (MAR) medical brace includes a flexible outer shell that fits around the anatomical area to be braced and a plurality of adjustable straps for securing the shell onto the anatomical area. The shell encases a MAR pack filled with magnetorheological fluid or gel. A plurality of magnets is attached to or encased in the shell to provide magnetic field acting on the MAR pack. The interaction of the magnetic field with the MAR pack adjustably increases or decreases the stiffness of the shell depending on the strength of the magnetic field. A control mechanism is provided for selective adjustment of the magnetic field and other functions.

Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

Abstract: A new family of therapeutics which provides a controlled-release delivery platform for non-steroidal anti-inflammatory agents on an ester or an ester-carbonate backbone is disclosed herein. These agents are reversible inhibitors of acetylcholinesterase and are thus useful for clinical conditions benefiting from inflammation suppression and cholinergic intervention. These compounds are of the general formula wherein n=0, 1; X=C, Si, and N+ and NSAID=ibuprofen, naproxen, indomethacin and diclofenac. Other embodiments are also disclosed.

Abstract: An apparatus and method is provided for healing and regeneration of live human and animal bodies and influencing interaction and intercommunication at the cellular level. The apparatus can include one or more environmental and/or body sensors. An electrical circuit can also be provided to produce a square or trapezoidal wave that is delivered to a transducer for application, preferably timed at specific frequencies Delta, Theta, Alpha, to Beta, based on information received from the one or more sensors. In certain embodiments, a DC power source can be provided which allows the apparatus to be portable. A wireless communication module can also be provided.

Abstract: A new natural oil personal care composition and system for treating damaged hair and/or supporting healthy hair and healthy hair growth. The composition comprises a blend of natural oils including Jamaican black castor oil, and one or more of natural sweet almond oil (preferably unrefined), pure avocado oil, and hemp seed oil (preferably unrefined). The oils are preferably organic. The composition is useful for repairing damaged, depleted and/or thinning hair due to various factors, including inadequate nutrition or overproduction of sebum, which can result in hair loss. The composition is also useful for repairing dry, frizzy, oily, dull (low shine), and brittle hair that has been naturally damaged by the elements (e.g. the sun, heat, wind, and/or cold), by wearing head gear or hair accessories that create friction with the hair surface (e.g. helmets, hair elastics and hair bands), by inappropriate or overuse use of hair styling tools (e.g.

Abstract: This disclosure relates to compounds containing both an NO-releasing moiety and an H2S-releasing moiety and the use of such compounds in treating inflammatory diseases, including cancers.

Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

Abstract: A magnetic coil system featuring a multi-layer structure, a spherical shape, or both allows for efficient generation of a gradient magnetic field that induces an electric field in air in a region proximate to the coil. By subjecting at least a portion of a person's brain to the induced electric field various psychiatric disorders can be treated.

Abstract: Synthetic probes for detecting the activity of enzymes that catalyze reactions of post-translationally modified cysteine residues are described. The probes include “turn-on” probes that include a carbamate linkage that is cleaved via an intramolecular reaction with a free thiol produced by an enzyme catalyzed activity. The probes also include ratiometric, Michael addition-based probes that respond to enzymatic activity by a change in structure that results in a change in fluorescence properties. Methods of using the probes to detect enzymatic activity and disease are described. For example, the probes can be used to detect enzymatic activity in a variety of samples, including live cells and heterogeneous tissues. In addition, prodrugs that can be activated by enzymes that catalyze reactions of post-translationally modified cysteine residues and methods of using the prodrugs to treat disease are described.

Abstract: It is an aspect of the present invention to provide a method for recording a response to Transcranial Magnetic Stimulation (TMS) utilizing a bi-phasic double pulse pair from a TMS coil device to stimulate a subject wherein the second pulse has a lower amplitude compared to the first pulse in the bi-phasic double pulse pair. Significant advantages are achieved using bi-phasic double pulse pairs, particularly where the second pulse in a pair has an intensity lower than the first. Obtaining measurements is simpler and more accurate as the number and intensity of stimulation can be reduced compared to standard single pulse stimulation.

Abstract: A system for treating neurological conditions by low-frequency time varying electrical stimulation includes an electrical device for applying such low-frequency energy, in a range below approximately 10 Hz, to the patient's brain tissue. An implantable embodiment applies direct electrical stimulation to electrodes implanted in or on the patient's brain, while a non-invasive embodiment causes a magnetic field to induce electrical currents in the patient's brain.

Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a cardiovascular disease in an individual using such pharmaceutical compositions.

Abstract: The use of selenite- or selenate-containing preparations supplemented with pharmaceutically acceptable or food-compatible acids for the preparation of an agent intended for topical or buccal application or mucosal administration is described.

Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

Abstract: A method for reducing, inhibiting, and eliminating inflammation and pain by using an effective amount of iron chelator composition to balance oxidative activity at a cutaneous site of inflammation and pain. The composition contained in transdermal formulations and administered topically in accordance with the invention can be combined with one or more suitable carriers and can be administered in conjunction with one or more additional therapeutic agents.

Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

Abstract: The present invention relates to process for preparing cosmetic compositions at two stages. The first relates to the preparation of organogels in which liquid oils are structured by a mixture of structuring agents such as monoglycerides and waxes, which also have the addition of other components such as polymers and polyol esters. The second step is the formation of the cold or hot process cosmetic compositions where emulsions are prepared by the addition of water, aqueous solutions and other components, to the organogel. The emulsions prepared have superior sensory, chemical-physical and stability characteristics, to those currently produced by the classic technology of preparation with emulsifiers.

Abstract: A combination of antibiotics including rifabutin, clarithromycin and clofazimine for the treatment of an autoimmune disease such as multiple sclerosis and related diseases. In a further aspect, there is provided a composition comprising a combination of two or more antibiotic agents for the treatment of an autoimmune disease, said two or more antibiotic agents selected from rifabutin, clofazimine, and at least one macrolide.

Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a cardiovascular disease in an individual using such pharmaceutical compositions.